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METHODS AND MATERIALS: Nonmetastatic prostate cancer patients treated with external
beam radiotherapy or brachytherapy in 2007 were randomly sampled from radiation oncology facil-
ities nationwide. Of 414 prostate cancer cases from 45 institutions, 86 received low-dose-rate bra-
chytherapy. We collected the 30-day postimplantation CT images of these patients and 10 test cases
from two other institutions. Scans were downloaded into a treatment planning system and prostate/
rectal contours were redrawn. Dosimetric outcomes were reanalyzed and compared with calculated
outcomes from treating institutions.
RESULTS: Median prostate volume was 33.4 cm3. Reevaluated median V100, D90, and V150 were
91.1% (range, 45.5e99.8%), 101.7% (range, 59.6e145.9%), and 53.9% (range, 15.7e88.4%),
respectively. Low gland coverage included 27 patients (39%) with a D90 lower than 100% of the
prescription dose (PD), 12 of whom (17% of the entire group) had a D90 lower than 80% of PD.
There was no correlation between D90 coverage and prostate volume, number of seeds, or implanted
activity. The median V100 for the rectum was 0.3 cm
3 (range, 0e4.3 cm3). No outcome differences
were observed according to the institutional strata. Concordance between reported and reevaluated
D90 values (defined as within 10%) was observed in 44 of 69 cases.
CONCLUSIONS: Central review of postimplantation CT scans to assess the quality of prostate
brachytherapy is feasible. Most patients achieved excellent dosimetric outcomes, yet 17% had less
than optimal target coverage by the PD. There was concordance between submitted target-coverage
parameters and central dosimetric review in 64% of implants. These findings will require further
validation in a larger cohort of patients.  2013 American Brachytherapy Society. Published by
Elsevier Inc. All rights reserved.Keywords: Prostate cancer; Brachytherapy; Quality assurance; Dosimetric outcomesmber 2011; received in revised form 5 April 2012;
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Prostate brachytherapy is widely practiced throughout
the United States and is used as an effective first-line
therapy for the management of patients with clinically
localized prostate cancer. Postprocedure evaluation of thehed by Elsevier Inc. All rights reserved.
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delivery to the prostate are routinely performed and consid-
ered standard of care. This quality assurance (QA) dosi-
metric assessment is based on the coordinates of the
implanted seeds within the prostate gland as noted on
a CT scan obtained 0e30 days after the procedure and
accounts as well for the strength, number of the radioactive
seeds, and their juxtaposition to the surrounding normal
tissues. Dosimetric parameters measured include the radia-
tion dose delivered to the prostate and the percentage of the
prescription dose (PD) exposed to rectum and urethra.
There have been several single- and multiinstitutional
series that have reported dosimetric outcomes after low-
dose-rate permanent interstitial prostate brachytherapy
(1e5). These reports have established expected standards
of implantation quality; and, in a number of these reports,
long-term tumor control outcomes have been linked to
the adequacy of the dose delivery to the prostate based
on the information obtained from this QA assessment
(6e8). However, there is a paucity of information concern-
ing the overall quality of implantation procedures as they
are performed in various academic and nonacademic
centers throughout the United States.
In an effort to obtain information regarding the overall
quality of permanent seed implantation procedures as per-
formed in the United States, Quality Research in Radiation
Oncology (QRRO) performed a random survey of centers
practicing prostate brachytherapy and obtained the postim-
plantation CT scans as well as dosimetric evaluations
performed based on these scans. In a unique process,
through a web-based remote deidentification process, post-
implantation scans were downloaded to a central site from
where they were extracted and underwent an independent
evaluation by an expert institution. This report will summa-
rize the dosimetric evaluation performed on these patients
and compare these measures of quality to the dosimetric
parameters submitted by the practicing institution.Methods and materials
Of 414 eligible prostate cancer cases from 45 surveyed
institutions, 86 patients received low-dose-rate brachyther-
apy and were eligible for this study. We collected CT
images, dose distributions, and contours from 59 of the
86 patients from 15 of 21 institutions with eligible cases.
Nineteen cases were not used owing to the inability to
retrieve the images (i.e., images no longer available in the
submitting institution’s computer planning system, images
stored in jpeg format only, or changes in software making
it impossible for the site to transfer image data without up-
dating software they no longer used); for eight cases,
portions of data were missing that would have been needed
to complete the dosimetric analysis. In addition, there were
10 test cases from two institutions that were initially used
from a community institution (which was similar to the restof the sampled cohort) and were included to increase the
number of cases evaluated for a final study cohort of 69
cases. Institutions in each of the four strata (academic, large
nonacademic, medium nonacademic, and small nonaca-
demic) participated.
Sample design
The QRRO survey used stratified two-stage cluster
sampling, with radiation oncology facilities from a master
list of those operating in the United States in 2007 being
stratified, a random sample of facilities selected from each
stratum, and a random sample of eligible cases selected
from each participating facility. Facility strata were classi-
fied as academic (main teaching hospital of a medical
school or National Cancer Institute-designated Comprehen-
sive Cancer Center), large nonacademic (facility with at
least three linear accelerators actively treating the patients),
medium nonacademic (facility with two linear accelerators
actively treating the patients), and small nonacademic
(facility with one linear accelerator actively treating the
patients). One hundred six facilities were selected and
invited to participate in a survey of radiation therapy prac-
tices, of which 45 (42%) participated in the study: 14
academic, 13 large nonacademic, 7 medium nonacademic,
and 11 small nonacademic facilities.
Case eligibility
Brachytherapy cases were randomly selected for review
and data abstraction using lists of eligible patients provided
by the treating facilities. Eligibility criteria for inclusion in
the survey were as follows: (1) biopsy-proven adenocarci-
noma of the prostate, (2) treatment that consisted of
a permanent interstitial implantation, (3) treatment received
during 1 year (2007), and (4) treatment in which the use of
androgen-deprivation therapy in conjunction with radio-
therapy was acceptable. Patients who had a prior radical
prostatectomy or were treated for recurrent/metastatic
disease were excluded. The characteristics of these patients
as well as brachytherapy treatment details are summarized
in Tables 1 and 2.
Data collection
Trained research associates performed onsite reviews of
the medical records of selected cases. Information about
patient characteristics; tumor characteristics; stagingworkup;
and brachytherapy treatment details, including isotope, seed
strength, number of seeds, and PD, were collected and re-
corded in an online database.
Digital Imaging and Communications in Medicine CT
images, contours of the prostate and rectum, and radiation
dose files (which were extracted from a variety of treatment
planning systems) were remotely deidentified and sub-
mitted from the sites to a control center at the Image-








Academic, n (%) 21 (36)
Nonacademic, n (%) 38 (64)
Prognostic risk group
Favorable, n (%) 39 (66)
Intermediate, n (%) 17 (29)
Unfavorable, n (%) 2 (3.4)
RT5 radiation therapy.
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the ITC to a treatment planning system (Variseed Varian
Brachytherapy, Charlottesville, VA) at the reference expert
institution for this study (Memorial SloaneKettering
Cancer Center) where the prostate and rectal anatomy were
recontoured by one physician (LM) and checked carefully
for accuracy by another (MJZ). Because these CT scans
were obtained 2e6 weeks after the implantation procedure,
a urinary catheter was not in place and delineation of the
urethra for contouring purposes was not obtained.
Based on the new contours and the seed locations,
doseevolume histograms were generated and dosimetric
evaluation was performed for each of these cases. Dosi-
metric parameters analyzed included %V100 prostate
(percent volume of the prostate that received the PD),
D90 prostate (dose delivered to 90% of the prostate ex-
pressed in percent of the PD), %V150 prostate (percent
volume of the prostate that received 150% of the PD),
V100 rectum (percent volume of the rectum that received
the PD), and D2cc rectum (dose to 2 cc of the rectum ex-
pressed in percent of the PD).
For the purposes of comparing the newly generated dosi-
metric evaluation to the submitted evaluation from the
treating institution, the new files were exported using
Digital Imaging and Communications in Medicine protocol
and uploaded to the ITC, where the files were registered to
the originally submitted treatment evaluations. The spatial
similarity between the submitted and reference expert pros-
tate contours was assessed using a Dice’s coefficient (9).Table 2
Brachytherapy treatment details
Parameter Number Range




Median V100, rectum (cc) 0.3 0e4.3
Median D2cc, rectum (%) 64 27e126Results
Dosimetric outcomes based on evaluation of reference
expert
The median prostate volume was 33.4 cm3 (range,
19.4e70.1 cm3). The median %V100, %D90, and %V150
were 91.1% (range, 45.5e99.8%), 101.7% (range,
59.6e145.9%), and 53.9% (range, 15.7e88.4%), respec-
tively. Low gland coverage was observed in some patients:
27 (39%) were noted to have a D90 lower than 100% of PD;
and of those, 12 (17%) had a D90 lower than 80% of the PD.
For this data set, there was no correlation between D90
coverage and prostate volume, number of seeds, or total im-
planted activity. In addition, there were no apparent differ-
ences in D90 dose coverage according to the different
institutional strata.
The median V100 for the rectum was 0.3 cc (range,
0e4.3 cc). The median D2cc rectum doses were 64.3%
(range, 27.3e126.1%). No differences were observed in
terms of dosimetric outcomes according to the institutional
strata.
Comparison of contours and dosimetric outcomes
between submitted data and reference expert data
The Dice’s coefficient was used to compare the
submitted and reviewed prostate volumes, as shown in
Fig. 1. The coefficient measures the intersection between
the two volumes to be compared; thus a Dice’s coefficient
of 1 means that the two volumes can be superimposed and
are equal. The average Dice’s coefficient for the prostate
volumes in these patients was 0.83 (range, 0.75e0.92) with
a standard deviation (SD) of 0.04.
The median and SD of %D90 for the submitted and re-
viewed scans were 101.5% (SD, 17.6%) and 101.1% (SD,
18.5%), respectively (Fig. 2). We define D90 concordance
to be good if the D90 value reported by the treatingFig. 1. Histogram of Dice’s coefficient values indicating the spatial
concordance of submitted and reviewed prostate volumes.
Fig. 2. Histogram of prostate pD90% values (percent of prostate receiving
90% of PD) for submitted and reviewed plans. PD5 prescription dose.
Fig. 4. Histogram of rectum pD2cc values (percent of PD covering hottest
2 cc) for submitted and reviewed plans. PD5 prescription dose.
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concordance was observed in 44 of the 69 cases.
The median and SD of %V100 for the submitted and re-
viewed scans were 88.1% (SD, 10.7%) and 87.9% (SD,
11.2%), respectively. For the submitted contours and calcu-
lated doses, there were 32 patients (46%) with D90 lower
than 100% of the PD and 18 patients (26%) with D90 lower
than 90% of the PD. When these contours were centrally
reviewed and doses were recalculated, 28 patients (41%)
were noted to have a D90 lower than 100% of the PD and
17 patients (25%) had a D90 lower than 90% of the PD.
Figure 3 illustrates the similarities between the
submitted and reviewer evaluations for %V150. As demon-
strated in Fig. 3, 4% and 7% of patients had V150 greater
than 80%, suggestive of a ‘‘hot implant’’ based on the
submitted and centrally reviewed dose calculations.
The average Dice’s coefficient for the rectal volumes in
these patients was 0.8369 (range, 0.7533e0.9165) with anFig. 3. Histogram of prostate pV150% values (percent of prostate receiving
greater than 150% PD) for submitted and reviewed plans. PD5 prescrip-
tion dose.SD of 0.0431. The median and SD of rectal D2cc as
a percentage of the PD was 62.7% (SD, 18.1) and 64.3%
(SD, 20.3) for the submitted and reviewed scans, respec-
tively (Fig. 4).
When all the above-mentioned analyses were performed
excluding the 10 test cases, the findings were found to be
not significantly different (data not shown).Discussion
To our knowledge, this is the first report summarizing
a concerted effort to evaluate the quality of prostate brachy-
therapy as part of a random survey of treating institutions
within the United States. One of the primary objectives of
QRRO is to assess the quality of care in radiation oncology
as practiced in theUnited States. In 2007e2008, QRRO initi-
ated a series of institutional surveys to evaluate the quality of
treatment delivery for prostate, lung, cervix, and breast
cancers based on the on-site evaluation of available treatment
records. As the quality of prostate brachytherapy is essen-
tially assessed primarily through the evaluation of the post-
implantation CT scans, QRRO initiated an elaborate QA
process to independently reevaluate the postimplantation
scans and reanalyze the dosimetric parameters that are surro-
gates for quality and adequacy of the dose delivery to the
prostate and normal tissues for patients treated with perma-
nent interstitial implantation. In addition to reevaluation of
the dosimetric parameters, this process would allow compar-
ison of the submitted evaluation to the evaluation performed
by an independent expert reviewer. Our report indicates that
this QA evaluation is feasible and may serve as an opportu-
nity for larger-scale QA assessments of individual institu-
tions practicing prostate brachytherapy.
For this report, we evaluated brachytherapy quality of
treatment delivery via a web-based remote deidentification
program that facilitated scans being transferred to a central
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referee institution. The latter reevaluation process entailed
recontouring and reassessing the dosimetric outcomes of
the electronically transferred postimplantation CT scans.
This exercise also afforded us the opportunity to compare
dosimetric outcomes as submitted by the treating institution
based on their internal QA review to that performed by the
referee institution. The successful implementation of
a central QA review has important implications not only
for gauging the quality of brachytherapy as performed in
the United States but also as a tool to provide external feed-
back and evaluate improvement of an individual’s perfor-
mance over time through serial assessments performed in
a consistent fashion. Such a process has been used in the
past for centralized review of eligibility of an institution;
the presence of basic skills for performing implantation
can be verified, to allow for institutional eligibility to enroll
patients into prospective cooperative group studies (10).
This process could be integrated in the future as part of
self-assessment exercises for individual institutions to eval-
uate the quality of their procedures performed compared
with other practicing centers.
Merrick et al. (11) have previously reported the dosi-
metric analysis of a large multiinstitutional database
consisting of 6600 prostate implantation procedures per-
formed by 129 brachytherapists from community practices.
Implants were performed using a preplanned technique and
the scans submitted to a commercial entity (Pro-Qura, Se-
attle, WA) for dosimetric analysis. The analysis technique
used for these patients consisted of placing an inverted T
on the preplan ultrasound and the corresponding postim-
plant CT axial image with the back of the T placed at the
posterior aspect of the prostate. The ultrasound and CT
images in this way were fused together to allow transfer
of the volumes drawn initially on the preimplant ultrasound
to be superimposed on the postimplantation CT scan. The
authors defined ‘‘excellent’’ target coverage as V100 of
90% or greater and D90 of 100% or greater. Using these
criteria, 48% of the implants were considered as having
excellent dosimetry. In an earlier report (12), these authors
defined a cohort of implants that were defined as ‘‘too
cool’’ with V100 lower than 80% and/or D90 lower than
90%. Using these latter criteria, the percent of implant
procedures that were ‘‘cool’’ and considered inadequate
ranged from 13% to 36%.
The value of the postimplantation CT assessment is well
recognized and considered the standard mode of post-
implantation quality assessment. Several reports have indi-
cated that the quality of the dose delivery to the prostate is
associated with long-term biochemical tumor control. Stock
et al. (2) had reported that D90 values lower than 140 Gy
were associated with a higher incidence of prostate-
specific antigen failure. A large multiinstitutional study
demonstrated that D90 greater than 130 Gy was associated
with an 8-year prostate-specific antigen relapse-free
survival of 93% compared with 76% among patients whohad posttreatment D90 values lower than 130 Gy (7).
Recently, investigators from Memorial SloaneKettering
Cancer Center have shown that D90 greater than 140 Gy
based on the dosimetric assessment of a postimplantation
CT scan obtained on the day of the brachytherapy proce-
dure predicted for improved long-term biochemical tumor
control (5). Notwithstanding these findings, it is important
to note that a dosimetric analysis indicative of suboptimal
dose coverage will not necessarily result in an inferior
tumor control outcome. Especially for patients with disease
confined to a particular region within the prostate where the
dose distribution happens to be adequate, tumor control
would be expected despite what may be considered inade-
quate dose coverage for the rest of the gland. We acknowl-
edge that there are limitations of the CT postimplantation
assessment, which include postprocedure edema that can
at times mistakenly characterize an implant as inadequate.
Nevertheless, the postimplantation CT as a QA assessment
is still considered standard of care after prostate brachyther-
apy and provides an opportunity for the radiation oncolo-
gist to perform a critical assessment of the inadequacies
of target coverage. With greater awareness of the brachy-
therapist’s target coverage and dose distributions achieved
after the procedure, patterns of deficiencies can be poten-
tially corrected with any necessary modifications of the
technical aspects of the procedure.
The data presented in this report demonstrate acceptable
quality outcomes based on dosimetric parameters assessed
from the postimplantation scans and consistent with the
finding of others (11e13). Although urethral dose assess-
ments were not possible in the absence of a urinary catheter
for anatomic visualization, the target coverage and rectal
dose assessments indicate that implant procedures were
generally performed well. Nevertheless, we observed that
nearly 20% of evaluated cases had %V100 less than 80%,
which we used as an indicator of suboptimal dose coverage
of the prostate. Published reports of single-institutional
dosimetric outcomes suggest that the percentage of cases
with suboptimal dose coverage using this parameter ranges
from 6% to 25% (14e23). We were not able to identify any
patterns or predictors of suboptimal target coverage with
the PD from particular institutions, or patterns within insti-
tutional strata (academic vs. nonacademic), number of
implant procedures performed yearly, prostate size, or other
patient-related characteristics. Our general impression in
such cases of suboptimal coverage was that the seed loca-
tion was predominately placed more inferiorly with re-
sultant cold areas at the base and at times superior
displacements with colder areas at the prostate apex. The
incidence of higher rectal doses was noted in 13% of eval-
uated cases (Fig. 4) and no obvious predictors for higher
rectal dosing were identified.
We recognize the limitations of this study, which include
its retrospective nature and the relatively small cohort of
postimplantation studies that were available for analysis. In
addition, there are known uncertainties associated with the
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postimplantation dosimetric analysis in particular at the pros-
tatic base and apex as well as the anterior aspect of the gland
with implanted seeds causing image artifact. Furthermore,
we acknowledge that accuracy may have been further
enhanced ifmultiple blinded observerswould have been used
to contour and recontour the images instead of as performed
in this study with one investigator and along with a second
physician to check for the accuracy of target delineation.
Our results nevertheless highlight the fact that not all
implantation procedures will produce optimal dose
delivery. In general, greater experience among practitioners
has been shown to correlate with reduced incidence of
poorly performed implant procedures. Yet we recognize
that even with significant procedural experience, subop-
timal target coverage with the PD can be observed even
among the most experienced practitioners. Advances in
real-time dosimetric evaluation and opportunities for accu-
rate intraoperative corrections will likely contribute to
further reductions in the likelihood of delivering subop-
timal dosing to the gland and increase the odds of achieving
greater consistency of dose delivery among practitioners.Conclusion
In conclusion, we have demonstrated the feasibility of
assessing the quality of prostate brachytherapy via remote
independent review as part of a survey of practicing institu-
tions in the United States. Our findings are consistent with
optimal tumor coverage with the PD achieved in most of
the treated patients. These data cannot be used to make
broad generalizations regarding the adequacy of tumor
coverage or quality of prostate brachytherapy procedures
as performed in the United States, given the small sample
size we analyzed. Yet it represents a study demonstrating
the feasibility to assess the quality of implant procedures
via a remote centrally located review. Such assessments
provide an opportunity for self-assessment and will likely
be used in the future as an important component for license
recertification, as this process could be used to demonstrate
proficiency of the practitioner.
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